-Reuters
BridgeBio Pharma Posts Updated Data From Muscular Dystrophy Trial, Plots Path To Market
BridgeBio Pharma Inc (NASDAQ: BBIO) has
Related Posts
Meridian Bioscience’s Q2 Revenues Increase 30% To $111M, Highest In Company History
Meridian Bioscience Inc (NASDAQ:VIVO) reported a 30% increase in Q2 sales to $111.2 million, the highest in the company’s history,…
Arbutus Reports Prelim. Data On Co.’s Capsid Inhibitor AB-836 Is Generally Safe, Well Tolerated, Provides Antiviral Activity
Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of assets with different modes of action to
Guggenheim Initiates Darden Restaurants With A Buy: ‘Good Times, Great Stock, Olive Garden’
Analysts at Guggenheim Partners had not rescinded their initial outlook that the restaurant industry would struggle to structurally grow margins as long as the unemployment rate stayed below 4%.
But the firm said Thursday it was betting on one group to outperform.